Abstract library

12 results for "biodistribution".
#1156 Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate
Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Dale Bailey
#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT
Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Sofie Van Binnebeek
#1251 Biodistribution and Radiation Dosimetry of a Novel 18F-Fluoroethyl Triazole [Tyr3] Octreotate Analogue for PET Imaging Patients with Advanced Neuroendocrine Tumours.
Introduction: Despite advances, detection and quantification of NET activity by imaging remains a challenge.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Suraiya Dubash
Authors: Dubash S, Keat N, Mapelli P, Twyman F, ...
Keywords: PET
#2947 Al18F-NOTA-Octreotide PET Imaging of the Somatostatin Receptor: First Comparison with 68Ga-DOTATATE in Neuroendocrine Tumor Patients
Introduction: Practical and economic challenges limit the widespread use of 68Ga-labeled somatostatin analog (SSA) PET, the current standard for somatostatin receptor imaging. A promising 18F-labeled SSA, Al18F-NOTA-octreotide (Al18F-OC), has recently been introduced.
Conference: 17th Annual ENETS Conference (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Elin Pauwels
#1321 Iodinated Exendin-4 Shows Improved Pharmacokinetic in Rat Insulinoma Model
Introduction: GLP-1 receptor is an important marker for imaging benign insulinomas.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Svetlana Rylova
Keywords: GLP-1, insulinoma
#3013 Structurally-Optimized Peptide VMT-Alpha-NET Enhances the Efficacy of SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors
Introduction: 203Pb/212Pb is a promising theranostics pair for SSTR2-targeted alpha-particle therapy for neuroendocrine tumors (NETs). The development of SSTR2-targeted peptides that are optimized for the Pb isotopes has the potential to improve performance.
Conference: 17th Annual ENETS Conference (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dongyoul Lee
Authors: Lee D, Li M, Baumhover N, Liu D, ...
#447 SOMscan: Towards a Ga-68-labeled Pan-Somatostatin PET Imaging Probe Based on SOM230 (Pasireotide)
Introduction: The somatostatin receptor subtype sst2 is largely expressed on neuroendocrine tumors. However, current clinical studies indicate that the subtypes sst1, 3, 5 are of substantial relevance as well.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Melpomeni Fani
Authors: Fani M, Braun F, Mann A, Kiewer A, ...
Keywords: SOM230, Ga-68, PET imaging
#516 Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT in Somatostatin Exopressing Organs and Tumors
Introduction: Octreotide derived radiolabelled peptides have been widely used for somatostatin receptor (sstr) imaging. Clinically used radiopeptides exclusively target sstr subtype 2. But radiolabeled Lanreotide has been claimed to bind sstr 2, 3 and 5.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emre Demirci
Authors: Kabasakal L, Demirci E, Ocak M, Aygun A, ...
Keywords: Octreotide PET
#1801 Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O
Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Guillaume Nicolas
Keywords: PRRT, 177Lu, OPS201
#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer
Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: DNB, FEBNM Sugandha Dureja
Authors: Dureja S, Thakral P, Pant V, Pallavi U, ...
Keywords: PRRT, radiosensitizer
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team